Open Orphan #ORPH – World’s first Covid-19 human challenge study to expand July 14, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan plc, is continuing to work with the UK Government to inoculate up to 20 further volunteers as part of the world’s first COVID-19 characterisation study. As part of the characterisation study, researchers aimed to identify a dose of COVID-19 that…

Open Orphan #ORPH – Launch of Disease in Motion platform April 9, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO , a subsidiary of Open Orphan, has officially launched its Disease in Motion® platform. This unique data-focused platform includes clinical, immunological, virological and digital (wearable) biomarkers. The Disease in Motion platform has multiple infectious disease applications that are applicable to a wide variety of…

Open Orphan #ORPH – COVID-19 Human Challenge Programme update March 25, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces an update in the world’s first COVID-19 characterisation study. Following Research Ethics Committee approval on 17 February 2021, hVIVO, a subsidiary of Open Orphan, began the study at the Royal Free London NHS Foundation Trust earlier this month. The first three volunteers have now successfully completed…

Open Orphan #ORPH – First volunteer dosed in intranasal COVID-19 vaccine clinical trial January 11, 2021 – Posted in: Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces that the first volunteer has been dosed with the Codagenix Inc. (“Codagenix”) needle free, intranasal COVID-19 vaccine, COVI-VAC. Conducted by hVIVO, part of Open Orphan plc, the Phase I clinical trial of COVI-VAC is being carried out at their facility in the UK. COVI-VAC is a single-dose, intranasal, live…

BRR Media – Open Orphan #ORPH secure MHRA approval to start Codagenix COVID-19 phase 1 vaccine trial December 14, 2020 – Posted in: Uncategorized

Open Orphan #ORPH – MHRA approval for nasal COVID-19 vaccine clinical trial – Posted in: Uncategorized

First in human trials for vaccine candidate with the potential to confer long-term immunity Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials, announces the first in human (Phase I) study of Codagenix intranasal SARS-CoV-2 (COVID-19) vaccine candidate has received approval from the UK’s independent Medicines and Healthcare Products Regulatory Agency (MHRA). Further to the…

(No title) November 16, 2020 – Posted in: Venture Life Group (VLG)

16th November, 2020 VENTURE LIFE GROUP PLC (“Venture Life” “VLG” or the “Company”) Cardiff University’s published in-vitro study reports two CPC-based mouthwashes completely eradicate SARS-CoV-2 (COVID-19) within a 30 second exposure Venture Life (AIM: VLG), a leader in developing, manufacturing and commercialising products for the self-care market, announced on 24 August 2020 its involvement in a UK-led clinical trial, with one of its key oral care brands containing the powerful Cetylpyridinium Chloride (“CPC”) technology, on those affected with COVID-19.…

Open Orphan #ORPH Awarded Contract From Codagenix Inc For COVID-19 Vaccine Trial July 27, 2020 – Posted in: Open Orphan (ORPH), Uncategorized

Tuesday 28th July, 2020 Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce a new contract with Codagenix Inc. (“Codagenix”) to conduct a first in human (Phase I) trial evaluating safety and immunogenicity of a single-dose, intranasal SARS-CoV-2 (COVID-19) vaccine candidate in 48 healthy young adult volunteers. Highlights: First in human…

Irish Independent – Open Orphan subsidiary starts testing drug for treating Covid-19 April 24, 2020 – Posted in: Open Orphan (ORPH)

by Ellie Donnelly A subsidiary of Open Orphan has started testing a drug that could potentially treat Covid-19. Open Orphan is a Europe- focused pharma services company specialising in rare disease and so-called orphan drugs. The tests are being carried out by its London-based subsidiary Hvivo on behalf of its client Nearmedic International. The drug being tested has both potential anti-viral and anti-inflammatory activity, and therefore could reduce both virus infectivity and disease severity respectively,…